Acute pancreatitis; frequency in diabetic patients taking combination of sitagliptin and metformin
Abstract
… Objectives: To determine the frequency of acute pancreatitis in patients taking sitagliptin and metformin. A study conducted on 100 type II diabetic patients. Study design: It is the descriptive case series study. Setting: It is a single center study conducted in the medicine department of Independent university hospital Faisalabad. Duration of study: From June 2015 to December 2015. Material and methods: 100 type II diabetic patients were taken and given combination of sitagliptin and metformin and observed for 6 months for signs and symptoms of acute pancreatitis. Results: out of 100 patients 39 (39%) were males, 61(61%) were females. Mean age of study population was 44.51±10.22. 13 (13%) were having diabetes of less than 3 years duration. 47 (47%) were having diabetes of 4 to 6 years duration, 17 (17%) were having diabetes of 7 to 9 years duration and 13 (13%) of the patients were having 13+ years duration. After 6 month of observation 79 (79%) of the patients appear to have symptom of all type of abdominal pain, 78 (78%) of the patients have had at least one episode of vomiting and 79 (79%) patient have had at least one episode of fever. These patient underwent serum amylase and serum lipase testing but none of them was found to have acute pancreatitis. Conclusions: Combination of sitagliptin and metformin causes gastrointestinal side effects but we found no case of acute pancreatitis associated with this medicine.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 100 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.